Serum Institute of India 's Chief Executive Officer Adar Poonawalla has said their Covovax vaccine will get approval as a booster against COVID-19 in the next 10 to 15 days. The vaccine works very ...

The World Health Organization (WHO) will hold a meeting next week to consider emergency use listing of Serum Institute of India’s (SII) Covid-19 vaccine Covovax. SII has a tie-up with US biotech ...

Serum Institute of India (SII) CEO Adar Poonawalla on Saturday said clinical trials of COVID-19 vaccine Covovax have begun in India and the company hopes to launch it by September this year.

In December, the country approved the Serum Institute of India's Covovax and Biological E's Corbevax for emergency use. It also approved ZyCoV-D vaccine - the world's first DNA vaccine against ...

New Delhi, Mar 4 (PTI) An expert panel of the country's central drug authority has recommended granting emergency use authorisation (EUA) to Serum Institute of India's COVID-19 vaccine Covovax for ...

and Shah Capital says that is a consequence of “reactive leadership and outdated and old-fashioned marketing,” particularly with regard to its COVID-19 vaccine Nuvaxovid/Covovax. The hedge ...

Sanofi – which has taken a sub-5% equity stake in Novavax for $70 million – said the alliance will expand access to the biotech’s protein-based adjuvanted COVID vaccine Nuvaxovid/Covovax ...

mRnA vaccines are still not available in India. But Serum Institute is making a local version of Novavax called Covovax - it has already exported 40 million doses. "Why is it not being approved as ...

He said the company already has six million booster doses of Covovax vaccine available and adults must take the booster shot. Proposing the uptake of newly approved COVID vaccine, the CEO of Serum ...